Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/04/2022* -- Results Q2 2022 -- -0.55 --
08/04/2022* 08:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.52 -0.59 11.16%
05/04/2022 08:30 EST Earnings Call Q1 2022 -- -- --
03/03/2022 -- Results Q4 2021 -0.59 -0.51 -15.12%
03/03/2022 08:30 EST Earnings Call Q4 2021 -- -- --
11/03/2021 -- Results Q3 2021 -0.58 -0.41 -43.21%
11/03/2021 08:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/04/2022
Beat/Miss Upgrade
Return Since -40.28%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
URL https://www.eyepointpharma.com
Investor Relations URL http://investors.eyepointpharma.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Aug. 04, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
17.27%
-64.52%
-36.84%
75.00%
-17.99%
-57.55%
86.02%
-40.77%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
--
--
24.37%
38.45%
2.00%
3.01%
-39.64%
-87.75%
--
--
--
--
--
-19.32%
-59.34%
-90.56%
--
--
89.34%
-25.97%
30.15%
136.8%
-62.13%
-49.27%
-6.46%
9.88%
60.13%
-0.98%
1.50%
27.61%
32.40%
14.71%
As of June 24, 2022.

Profile

Edit
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
URL https://www.eyepointpharma.com
Investor Relations URL http://investors.eyepointpharma.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Aug. 04, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FRBRX 11.32M USD 1.43%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter EYPT Tweets